Impact of metformin on immunological markers: Implication in its anti-tumor mechanism

• Published in: Pharmacology & therapeutics (Oxford) Vol. 213; p. 107585
• Main Authors: Chen, George G., Woo, Peter Y.M., Ng, Stephanie C.P., Wong, George K.C., Chan, Danny T.M., van Hasselt, Charles A., Tong, Michael C.F., Poon, Wai Sang
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01.09.2020
• Subjects: Cancers; Immune system; Immunotherapy; Metformin; NGAL; YAP1; TAM; Tregs; NF-kB; TSP1; HCC; NGF; EMT; TME; ESCC; NETs; Immunotherapy; HNSCC; Cancers; PD-L1; AMPK; Metformin; TILs; TNBC; HIF1α; PD-1; Immune system
• ISSN: 0163-7258; 1879-016X
• DOI: 10.1016/j.pharmthera.2020.107585

Metformin, an anti-hyperglycemic drug, has been known to have antitumor properties for around 15 years. Although there are a number of reports attributing the antitumor function of metformin to its impact on energy homeostasis and oxygen re-distribution in tumor microenvironment, detailed mechanisms remain largely unknown. In the past several years, there is an increasing number of publications indicating that metformin can affect various immunological components including lymphocytes, macrophages, cytokines and several key immunological molecules in both human and animal studies. These interesting results appear to be in line with emerging data that suggest associations between immune responses and energy homeostasis/oxygen re-distribution, which may explain effective impacts of metformin on immunotherapies against autoimmune diseases as well as cancers. This review article is to analyse and discuss recent development in the above areas with aim to justify metformin as a new adjuvant for immunotherapy against human cancers. We hope that our summary will help to optimize the application of metformin for various types of human cancers.